ReviewClinics in geriatric medicine2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.
Review in Clinics in geriatric medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04602273 (Treatment of High Risk Myelodysplastic Syndromes), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation.JCO clinical cancer informatics · 2022Trial
- Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.Blood advances · 2022Trial
- Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome.Chinese journal of integrative medicine · 2017Trial
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.The New England journal of medicine · 2016Trial
- Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.British journal of haematology · 2026Article
- Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population.Future oncology (London, England) · 2025Article
- Nutrition and Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults (Aged ≥60): A Scoping Review.Journal of the Academy of Nutrition and Dietetics · 2025Article
- Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.Annals of hematology · 2025Article
- Cytogenetic profile and risk of transformation to acute myeloid leukemia (AML) in Indonesian patients with myelodysplastic syndrome (MDS): a pilot study.F1000Research · 2024Article
- Article
- Review
- Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea.Yonsei medical journal · 2023Article
- Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2022Article
- Article
- The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia.iScience · 2021Article
- MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models.Cell death discovery · 2021Article
- 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line.PloS one · 2021Article
- (2Cancers · 2020Article
- Understanding intrinsic hematopoietic stem cell aging.Haematologica · 2020Review
- Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.Journal of medical Internet research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic diseases that frequently affect older adults. Treatment is challenging. Management of older adults with MDS and AML needs to be individualized, accounting for both the heterogeneity of disease biology and patient characteristics, which can influence life expectancy and treatment tolerance. Clinical trials accounting for the heterogeneity of tumor biology and physiologic changes of aging are needed to define optimal standards of care. This article highlights key evidence related to the management of older adults with MDS and AML and highlights future directions for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.